open access

Vol 66, No 1 (2015)
Original papers
Published online: 2015-03-02
Submitted: 2014-01-29
Accepted: 2014-06-05
Get Citation

Comparison of chromogranin A (CgA) levels in serum and plasma (EDTA2K) and the respective reference ranges in healthy males

Piotr Glinicki, Wojciech Jeske, Renata Kapuścińska, Wojciech Zgliczyński
DOI: 10.5603/EP.2015.0009
·
Endokrynologia Polska 2015;66(1):53-56.

open access

Vol 66, No 1 (2015)
Original papers
Published online: 2015-03-02
Submitted: 2014-01-29
Accepted: 2014-06-05

Abstract

<!--[if gte mso 9]> Normal 0 21 false false false PL X-NONE X-NONE <![endif]-->

Introduction: Chromogranin A (CgA) is a major, nonspecific marker of neuroendocrine tumours (NET). There are a few routinely used assays for the measurement of CgA concentration in serum or plasma. These assays differ in analytical techniques (radioimmunoassay, ELISA, CLIA, TRACE), have different calibrators, and use different antibodies which recognise different epitopes of CgA molecule. Our study was designed to confirm the noted earlier differences in CgA levels measured in serum and plasma, and to establish respective reference ranges in a group of healthy males.

Material and methods: In 145 male blood donors (age 19–61 years, mean = 35.7), blood was collected into two tubes: one with EDTA2K (plasma) and one with clot activator (serum). Chromogranin A was measured by immunoradiometric kit (CIS bio, France).

Results: In blood donors, the median (and the range) of CgA concentration were as follows for serum samples — 42.0 ng/mL (16–108 ng/mL) and for plasma (EDTA2K) samples — 58.0 ng/mL (23–153 ng/mL). The differences between serum and plasma ranged 15–75% (median 26%). Plasma CgA levels were significantly higher in relation to serum CgA levels (p &lt; 0.0001). Correlation of CgA in serum and plasma was r = 0.8493; p &lt; 0.01. The reference ranges for CgA measured in serum and plasma in males, expressed as 2.5 to 97.5 percentiles, were: 21.0–108.0 ng/mL and 31.0–153.0 ng/mL respectively.

Conclusions:

1. Significant differences in the concentrations of CgA measured in plasma and in serum demand the application of separate reference ranges adjusted to the type of investigated material.

2. Each laboratory should recommend only one sort of sample material for CgA assay.

 

<!--[if gte mso 9]> <![endif]--><!--[if gte mso 10]> <! /* Style Definitions */ table.MsoNormalTable {mso-style-name:Standardowy; mso-tstyle-rowband-size:0; mso-tstyle-colband-size:0; mso-style-noshow:yes; mso-style-priority:99; mso-style-qformat:yes; mso-style-parent:""; mso-padding-alt:0cm 5.4pt 0cm 5.4pt; mso-para-margin-top:0cm; mso-para-margin-right:0cm; mso-para-margin-bottom:10.0pt; mso-para-margin-left:0cm; line-height:115%; mso-pagination:widow-orphan; font-size:11.0pt; font-family:"Calibri","sans-serif"; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:"Times New Roman"; mso-fareast-theme-font:minor-fareast; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin;} --> <!--[endif] -->

Abstract

<!--[if gte mso 9]> Normal 0 21 false false false PL X-NONE X-NONE <![endif]-->

Introduction: Chromogranin A (CgA) is a major, nonspecific marker of neuroendocrine tumours (NET). There are a few routinely used assays for the measurement of CgA concentration in serum or plasma. These assays differ in analytical techniques (radioimmunoassay, ELISA, CLIA, TRACE), have different calibrators, and use different antibodies which recognise different epitopes of CgA molecule. Our study was designed to confirm the noted earlier differences in CgA levels measured in serum and plasma, and to establish respective reference ranges in a group of healthy males.

Material and methods: In 145 male blood donors (age 19–61 years, mean = 35.7), blood was collected into two tubes: one with EDTA2K (plasma) and one with clot activator (serum). Chromogranin A was measured by immunoradiometric kit (CIS bio, France).

Results: In blood donors, the median (and the range) of CgA concentration were as follows for serum samples — 42.0 ng/mL (16–108 ng/mL) and for plasma (EDTA2K) samples — 58.0 ng/mL (23–153 ng/mL). The differences between serum and plasma ranged 15–75% (median 26%). Plasma CgA levels were significantly higher in relation to serum CgA levels (p &lt; 0.0001). Correlation of CgA in serum and plasma was r = 0.8493; p &lt; 0.01. The reference ranges for CgA measured in serum and plasma in males, expressed as 2.5 to 97.5 percentiles, were: 21.0–108.0 ng/mL and 31.0–153.0 ng/mL respectively.

Conclusions:

1. Significant differences in the concentrations of CgA measured in plasma and in serum demand the application of separate reference ranges adjusted to the type of investigated material.

2. Each laboratory should recommend only one sort of sample material for CgA assay.

 

<!--[if gte mso 9]> <![endif]--><!--[if gte mso 10]> <! /* Style Definitions */ table.MsoNormalTable {mso-style-name:Standardowy; mso-tstyle-rowband-size:0; mso-tstyle-colband-size:0; mso-style-noshow:yes; mso-style-priority:99; mso-style-qformat:yes; mso-style-parent:""; mso-padding-alt:0cm 5.4pt 0cm 5.4pt; mso-para-margin-top:0cm; mso-para-margin-right:0cm; mso-para-margin-bottom:10.0pt; mso-para-margin-left:0cm; line-height:115%; mso-pagination:widow-orphan; font-size:11.0pt; font-family:"Calibri","sans-serif"; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:"Times New Roman"; mso-fareast-theme-font:minor-fareast; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin;} --> <!--[endif] -->
Get Citation

Keywords

chromogranin A; CgA; neuroendocrine tumour; NET

About this article
Title

Comparison of chromogranin A (CgA) levels in serum and plasma (EDTA2K) and the respective reference ranges in healthy males

Journal

Endokrynologia Polska

Issue

Vol 66, No 1 (2015)

Pages

53-56

Published online

2015-03-02

DOI

10.5603/EP.2015.0009

Bibliographic record

Endokrynologia Polska 2015;66(1):53-56.

Keywords

chromogranin A
CgA
neuroendocrine tumour
NET

Authors

Piotr Glinicki
Wojciech Jeske
Renata Kapuścińska
Wojciech Zgliczyński

Important: This website uses cookies.tanya dokter More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl